查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439376

Orthobiologics - 全球市場回顧、競爭格局、市場預測 (2030)

Orthobiologics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按訂單生產 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2020年全球骨科生物製品市場規模為53.3億美元，預計2030年將達到68.4億美元，2024-2030年預測期間複合年增長率為4.44%。骨科生物製品的需求不斷增長，主要是由於人口老化帶來的負擔增加，容易患各種骨退化性疾病，以及遭受交通事故和運動傷害等創傷的患者數量不斷增加。此外，主要製造商增加研發和合作研究的投資、增加各種骨科生物製品的批准等也預計將加強全球骨科生物製品市場。

骨科生物製劑市場動態

由於人口老化負擔日益加重，骨關節炎和退化性椎間盤疾病等骨退化性疾病更容易發生，骨科生物製劑市場目前正在快速擴張。根據聯合國《2019年世界人口老化要點》 "World Population Ageing 2019 highlights" ，全球約有7.03億人年齡在65歲或以上。報告也預計，到2050年，老年人口將增加至15億。

此外，根據世界衛生組織（WHO）2022年的統計數據，到2020年，全球60歲及以上的人口將達到約10億。

此外，根據骨關節炎行動聯盟Osteoarthritis Action Alliance(OAAA) (2020) 提供的數據，2019 年，全球約有2.42 億人患有骨關節炎(OA)，這是一種常見的關節炎形式，患有症狀和活動受限。另據報道，2019年，約43%的OA患者年齡在65歲或以上，88%的患者年齡在45歲或以上。

此外，近年來各種骨科生物製品的批准和上市也預計將快速成長骨科生物製品市場。例如，2019年2月28日，Medtronic宣佈用於脊椎和骨科手術的脫礦骨基質（DBM）骨移植產品Grafton於2018年8月獲得日本醫藥品醫療器材綜合機構（PMDA）批准（TM）已在日本上映。

因此，所有上述因素預計將推動全球骨科生物製品市場在預測期內快速成長。

然而，與骨科生物治療相關的高成本和嚴格的監管審批流程可能成為骨科生物市場的限制因素。

由於COVID-19大流行的爆發，骨科生物製劑市場的成長放緩。這是因為大流行期間許多擇期手術被推遲。此外，由於全國範圍內的封鎖而導致診所暫時關閉、由於COVID-19 大流行期間實施的物流限製而導致供應中斷，以及醫院將重點轉向COVID-19 管理，這些因素也都促進了骨科生物製品的需求，並產生了影響。然而，各種疫苗的推出和大規模疫苗接種活動已恢復正常運行，導致疫情後骨科生物製劑市場的成長。

骨科生物製劑市場區隔分析

在骨科生物製品領域，關節內替代療法產品預計將在未來幾年佔據重要的市場份額。這是由於世界人口中骨關節炎的盛行率很高。根據Osteoarthritis Foundation International（OAFI Foundation）2020年發佈的數據，全球估計有5億人患有骨關節炎，其中以髖關節和膝關節骨關節炎最為常見。關節內替代治療產品因其在治療有症狀的膝骨關節炎期間具有減輕疼痛的作用和較少的副作用而被廣泛採用，有助於骨科生物製劑市場的細分市場增長。

此外，關節內替代治療產品（包括一次、三次和五次注射）的廣泛使用預計也將促進該細分市場的成長。

本報告提供了全球骨科生物製品市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

目錄

第一章骨科生物製品市場報告簡介

第二章骨科生物製品市場概要

  • 調查範圍
  • 市場概況
  • 競爭評估
  • 財務基準

第三章 法規與專利分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第四章骨科生物製品市場關鍵因素分析

  • 骨科生物製品市場的驅動因素
    • 交通事故、跌倒等造成的傷害增加
    • 老年人的負擔增加，他們更容易罹患退化性骨骼疾病
    • 增加各種骨科生物製劑的批准和上市
    • 增加企業對骨科生物製劑開發的投資
  • 骨科生物製品市場的限制與挑戰
    • 骨科生物產品和治療的成本高昂
    • 嚴格的監管審批
  • 骨科生物製劑市場機遇
    • 大公司旨在擴大市場的策略性業務活動也提供了成長機會。
    • 新興國家對骨科生物製品的需求不斷增長

第五章波特的骨科生物五力分析

第六章 COVID-19 對骨科生物製品市場的影響分析

第七章 骨科生物製劑市場佈局

  • 按產品類型
    • 關節內替代治療產品
    • 脫礦骨基質
    • 骨形態發生蛋白
    • 合成人造骨
    • 骨移植
    • 其他
  • 按用途
    • 骨關節炎
    • 脊柱融合術
    • 軟組織損傷
    • 骨折恢復
    • 顎面和牙科應用
  • 按最終用戶
    • 醫院
    • 骨科診所
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第 8 章 Orthobiologics：全球公司份額分析 - 3 至 5 家主要公司

第九章 Orthobiologics 公司及產品簡介

  • Medtronic
  • Stryker
  • Collagen Matrix, Inc.
  • Arthrex, Inc.
  • Bioventus
  • Sanofi
  • Seikagaku Corporation
  • DePuy Synthes (Johnson & Johnson)
  • Globus Medical
  • Zimmer Biomet
  • NuVasive Inc.
  • SeaSpine
  • Baxter
  • Exactech, Inc.
  • RTI Surgical
  • Biomatlante
  • Fidia Farmaceutici S.p.A
  • LG Chem
  • TERUMO BCT, INC.
  • Anika Therapeutics, Inc.
  • Orthofix Medical Inc.
  • Kuros Biosciences
  • XTANT MEDICAL
  • APTISSEN
  • BONESUPPORT AB

第10章 KOL觀點

第十一章專案方法

第 12 章. 關於 DelveInsight

第十三章 免責聲明與聯絡資訊

Product Code: DIMDCL0173

Orthobiologics Market By Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, Others), By Application (Osteoarthritis, Spinal Fusion, Reconstructive & Fracture Recovery, Soft-Tissue Injuries, Maxillofacial And Dental Applications), By End-User (Hospitals, Orthopaedic Clinics, And Others), by geography, is projected to expand at a significant CAGR till 2030 owing to the growing number of sports injuries & road accidents and increasing prevalence of bone degeneration diseases across the globe.

The global orthobiologics market was valued at USD 5.33 billion in 2020, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030, in order to reach USD 6.84 billion by 2030. The escalating demand for orthobiologics is predominantly attributed to the rising burden of the geriatric population who are susceptible to developing various bone degenerative disorders, increasing cases of traumatic injuries such as road crashes, sports injuries, and others. Moreover, growing investments in research & development and collaborations by key manufacturers, and the rise in various orthobiologic product approvals, among others are also expected to bolster the global orthobiologics market.

Orthobiologics Market Dynamics:

The market for orthobiologics is expanding at a faster pace at present owing to the growing burden of the geriatric population who are more susceptible to developing bone degenerative disorders such as osteoarthritis, degenerative disc disorders, and others. According to the United Nations World Population Ageing 2019 highlights, approximately 703 million people were aged 65 years and above across the globe. Also, the report estimated the old age population to rise to 1.5 billion by the year 2050.

In addition, as per the World Health Organization 2022 statistics, globally, there were about 1 billion persons aged 60 years or over in the year 2020.

Furthermore, as per the data published by the Osteoarthritis Action Alliance (OAAA), 2020, in the year 2019, about 242 million people worldwide suffer from symptomatic and activity limiting osteoarthritis (OA) which is one of the common types of arthritis. The data also mentioned that about 43% of people with OA are 65 or older and 88% of people with OA are 45 or older in 2019.

In addition, the recent approval and launch of various orthobiologic products are also anticipated to surge the market for orthobiologics. For instance, on February 28, 2019, Medtronic launched the Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopedic procedures in Japan which was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in August 2018.

Hence, all the above-mentioned factors are expected to spike the global orthobiologics market during the forecasted period.

However, high costs associated with orthobiologics treatment and stringent regulatory approval processes are likely to impede the market for orthobiologics.

Due to the outbreak of the COVID-19 pandemic, the market for orthobiologics witnessed slow growth. This is due to the delay in the number of elective procedures during the pandemic. Moreover, temporary shut down of clinics due to nationwide lockdown, disruption in supply because of logistical restrictions imposed at the time of COVID-19 wave, and hospitals shifting their focus towards COVID management also affected the orthobiologics demand. However, the launch of various vaccines and mass vaccination drives have resume normal operations further leading to the growth of the orthobiologics market during the post-pandemic.

Orthobiologics Market Segment Analysis:

Orthobiologics Market By Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, Others), By Application (Osteoarthritis, Spinal Fusion, Reconstructive & Fracture Recovery, Soft-Tissue Injuries, Maxillofacial And Dental Applications), By End-User (Hospitals, Orthopaedic Clinics, And Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the orthobiologics product segment, the viscosupplementation products are projected to hold a significant market share in the forthcoming years. This is because of the high prevalence of osteoarthritis among the world's population. According to the data published by the Osteoarthritis Foundation International (OAFI Foundation) in the year 2020, worldwide, an estimated 500 million people have osteoarthritis, hip and knee osteoarthritis being the most common. Extensive adoption of viscosupplementation products for their effectiveness in reducing pain, and fewer side effects while treating symptomatic knee osteoarthritis will contribute to the segmental growth of the orthobiologics market.

Moreover, the wide availability of viscosupplementation products including single, three, and five injections is also anticipated to boost the segmental growth.

Furthermore, approvals of various viscosupplementation devices in the market will also augment the market. For instance, in 2019, Fidia Farmaceutici S.p.A. received Food & Drug Administration (FDA) regulatory approval for TRILURON(TM), a single-use syringe, prefilled with sodium hyaluronate to provide relief to the pain associated with osteoarthritis for up to six months.

Also, rising manufacturers' initiatives to launch viscosupplementation products will surge the market. For instance, in May 2019, Lupin Limited and Aptissen S.A. entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute, and sell the current Aptissen products in Canada which includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis.

Thus, all the aforementioned factors are expected to drive the segmental growth of the orthobiologics market during the forecasted period.

North America is expected to dominate the Overall Orthobiologics Market:

Among all the regions, North America is expected to hold a major share in the overall orthobiologics market during the forecasted period. This domination is owing to the rising incidents of traumatic injuries due to falls, accidents, and others in the region. Moreover, increasing geriatric and obese people in the region, growing incidences of spinal disorders, and rising physician and patient awareness about newly introduced orthobiologic treatment procedures and technologies will further bolster the market for orthobiologics in the region.

For instance, in the US, an overall 48.3 million people suffered from traumatic injuries out of which motor-vehicle incidents totaled 4.5 million in the year 2019 as per the National Safety Council 2022 report.

Additionally, as per the 2022 statistics published by the Centers for Disease Control and Prevention, the prevalence of obesity in the US was 42.4% in the year between 2017 and 2018.

According to research, it has been concluded that obese people have reduced bone density which increases the risk of fractures.

Moreover, the presence of key players such as Arthrex Inc., Stryker Corporation, Medtronic, among others, and their strategic business activities for the development of new orthobiologics for the treatment of various bone-associated disorders will propel the orthobiologics market in the region. For instance, on November 11, 2020, Stryker acquired Wright Medical Group N.V. a leading medical device company focused on extremities and biologics to enhance its market position.

Also, in June 2019, Bioventus entered into a development collaboration agreement with MTF Biologics to co-develop the next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA).

Further, the Asia-Pacific region has the future potential growth for the Global orthobiologics market. This is due to the rising geriatric population in the region. According to the Organisation for Economic Cooperation and Development (OECD) 2022 statistics, across lower-middle and low-income Asia-Pacific countries, the share of the population aged 80 years and over is expected to triple between 2020 and 2050. The rising old age population is more susceptible to musculoskeletal disorders such as arthritis, osteoarthritis, and others. Thus, the expanding aging population could contribute to the orthobiologics market growth in the region. Furthermore, according to the Australian Institute of Health and Welfare 2020 report, from the years 2017 to 2018, one in eleven Australians have osteoarthritis making it approximately 2.2 million people in the nation. Thus, the rising prevalence of joint degeneration disorders will increase the demand for orthobiologics.

In addition, the presence of well-established market players such as Seikagaku Corporation, LG Chem., TERUMO BCT, INC., among others, the rising disposable income, improving healthcare facilities in the region are the factors expected to grow the market in the region.

Orthobiologics Market Key Players:

Some of the key market players operating in the Orthobiologics market include Medtronic, Stryker, Collagen Matrix, Inc., Arthrex, Inc., Bioventus, Sanofi, Seikagaku Corporation, DePuy Synthes (Johnson & Johnson), Globus Medical, Zimmer Biomet, NuVasive Inc., SeaSpine, Baxter, Exactech, Inc., RTI Surgical, Biomatlante, Fidia Farmaceutici S.p.A, LG Chem, TERUMO BCT, INC., Anika Therapeutics, Inc., Orthofix Medical Inc., Kuros Biosciences, XTANT MEDICAL, APTISSEN, BONESUPPORT AB, and others.

Recent Developmental Activities in the Orthobiologics Market:

On July 28, 2022, Orthofix Medical Inc., launched fiberFUSE strip, an advanced demineralized fiber bone graft solution containing cancellous bone in the US.

On July 13, 2022, RTI Surgical entered into a long-term strategic agreement with Exatech for the development and supply of biologic bone substitutes. As part of the agreement, RTI Surgical acquired Exactech's Optecure®, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities.

On August 24, 2020, Xtant Medical Holdings, Inc. launched its Matriform® Si, a silicated synthetic bone graft strip designed and cleared for spinal fusion procedures in the US.

Key Takeaways from the Orthobiologics Market Report Study

  • Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Orthobiologics market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the Global Orthobiologics Market.
  • Various opportunities available for the other competitor in the Orthobiologics Market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Orthobiologics market growth in the coming future?

Target Audience who can be benefited from the Orthobiologics Market Report Study

  • Orthobiologics providers
  • Research organizations and consulting companies
  • Orthobiologics-related organization, association, forum, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders in Orthobiologics
  • Various End-users who want to know more about the Orthobiologics Market and the latest technological developments in the Orthobiologics market.

Frequently Asked Questions for the Orthobiologics Market:

1. What are Orthobiologics?

Orthobiologics are substances used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are often made from substances that are naturally found in the body.

2. What is the market for Global Orthobiologics?

The global Orthobiologics Market was valued at USD 5.33 billion in 2020, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030 to reach USD 6.84 billion by 2030.

3. What are the drivers for Global Orthobiologics?

The major factors driving the demand for orthobiologics are the growing prevalence of joint degenerative disorders such as arthritis, osteoarthritis, and increasing cases of traumatic injuries due to sports injuries, road crashes, and others. Moreover, a rise in investments by key manufacturers for the R&D and commercialization of orthobiologics, and growing product approvals, among others are also projected to boost the global orthobiologics market.

4. What are the key players operating in Global Orthobiologics?

Some of the key market players operating in the Orthobiologics market include Medtronic, Stryker, Collagen Matrix, Inc., Arthrex, Inc., Bioventus, Sanofi, Seikagaku Corporation, DePuy Synthes (Johnson & Johnson), Globus Medical, Zimmer Biomet, NuVasive Inc., SeaSpine, Baxter, Exactech, Inc., RTI Surgical, Biomatlante, Fidia Farmaceutici S.p.A, LG Chem, TERUMO BCT, INC., Anika Therapeutics, Inc., Orthofix Medical Inc., Kuros Biosciences, XTANT MEDICAL, APTISSEN, BONESUPPORT AB, and others.

5. Which region has the highest share in the Orthobiologics market?

Among all the regions, North America is expected to hold a major share in the overall orthobiologics market during the forecasted period, 2024-2030. This domination is owing to the rising incidents of traumatic injuries due to falls, accidents, and others in the region. Moreover, increasing geriatric and obese people in the region, growing incidences of spinal disorders, and rising physician and patient awareness about newly introduced orthobiologic treatment procedures and technologies will further bolster the market for orthobiologics in the region.

Table of Contents

1.Orthobiologics Market Report Introduction

2.Orthobiologics Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Orthobiologics Market Key factors analysis

  • 4.1 Orthobiologics Market Drivers
    • 4.1.1 Growing cases of traumatic injuries due to traffic clashes, fall, and others
    • 4.1.2 The increasing burden of the old age population susceptible to develop degenerative bone diseases
    • 4.1.3 Rise in approval and launch of various orthobiologics
    • 4.1.4 Rise in investments by companies for the development of orthobiologics
  • 4.2 Orthobiologics Market Restraints and Challenges
    • 4.2.1 High cost of the orthobiologic products and treatment
    • 4.2.2 Stringent regulatory approvals
  • 4.3 Orthobiologics Market Opportunities
    • 4.3.1 Strategic business activities by key players for market expansion also provide growth opportunities
    • 4.3.2 Growing demand for orthobiologics in emerging countries

5. Orthobiologics Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Orthobiologics Market

7. Orthobiologics Market layout

  • 7.1 By Product Type
    • 7.1.1 Viscosupplementation Products
    • 7.1.2 Demineralized Bone Matrices
    • 7.1.3 Bone Morphogenic Protein
    • 7.1.4 Synthetic Bone Substitutes
    • 7.1.5 Bone grafts
    • 7.1.6 Others
  • 7.2 By Application
    • 7.2.1 Osteoarthritis
    • 7.2.2 Spinal Fusion
    • 7.2.3 Soft-tissue Injuries
    • 7.2.4 Fracture Recovery
    • 7.2.5 Maxillofacial and Dental Applications
  • 7.3 By End-user
    • 7.3.1 Hospitals
    • 7.3.2 Orthopaedic Clinics
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 North America Orthobiologics Market, by Product Type
      • 7.4.1.2 North America Orthobiologics Market, by Application
      • 7.4.1.3 North America Orthobiologics Market, by End User
      • 7.4.1.4 North America Orthobiologics Market, by Country
      • 7.4.1.4.1 United States
      • 7.4.1.4.2 Canada
      • 7.4.1.4.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 Europe Orthobiologics Market, by Product Type
      • 7.4.2.2 Europe Orthobiologics Market, by Application
      • 7.4.2.3 Europe Orthobiologics Market, by End User
      • 7.4.2.4 Europe Orthobiologics Market, by Country
      • 7.4.2.4.1 France
      • 7.4.2.4.2 Germany
      • 7.4.2.4.3 United Kingdom
      • 7.4.2.4.4 Italy
      • 7.4.2.4.5 Spain
      • 7.4.2.4.6 Russia
      • 7.4.2.4.7 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 Asia-Pacific Orthobiologics Market, by Product Type
      • 7.4.3.2 Asia-Pacific Orthobiologics Market, by Application
      • 7.4.3.3 Asia-Pacific Orthobiologics Market, by End User
      • 7.4.3.4 Asia-Pacific Orthobiologics Market, by Country
      • 7.4.3.4.1 China
      • 7.4.3.4.2 Japan
      • 7.4.3.4.3 India
      • 7.4.3.4.4 Australia
      • 7.4.3.4.5 South Korea
      • 7.4.3.4.6 Rest of Asia Pacific
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 RoW Orthobiologics Market, by Product Type
      • 7.4.4.2 RoW Orthobiologics Market, by Application
      • 7.4.4.3 RoW Orthobiologics Market, by End User
      • 7.4.4.4 RoW Orthobiologics Market, by Region
      • 7.4.4.1 Middle East
      • 7.4.4.2 Africa
      • 7.4.4.3 South America

8. Orthobiologics Global Company Share Analysis - Key 3-5 Companies

9. Orthobiologics Company and Product Profiles

  • 9.1 Medtronic
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Stryker
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Collagen Matrix, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Arthrex, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Bioventus
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Seikagaku Corporation
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 DePuy Synthes (Johnson & Johnson)
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Globus Medical
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Zimmer Biomet
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 NuVasive Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 SeaSpine
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Baxter
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 Exactech, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 RTI Surgical
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Biomatlante
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Fidia Farmaceutici S.p.A
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 LG Chem
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 TERUMO BCT, INC.
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 Anika Therapeutics, Inc.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy
  • 9.21 Orthofix Medical Inc.
    • 9.21.1. Company Overview
    • 9.21.2. Company Snapshot
    • 9.21.3. Financial Overview
    • 9.21.4 Product Listing
    • 9.21.5. Entropy
  • 9.22 Kuros Biosciences
    • 9.22.1. Company Overview
    • 9.22.2. Company Snapshot
    • 9.22.3. Financial Overview
    • 9.22.4 Product Listing
    • 9.22.5. Entropy
  • 9.23 XTANT MEDICAL
    • 9.23.1. Company Overview
    • 9.23.2. Company Snapshot
    • 9.23.3. Financial Overview
    • 9.23.4 Product Listing
    • 9.23.5. Entropy
  • 9.24 APTISSEN
    • 9.24.1. Company Overview
    • 9.24.2. Company Snapshot
    • 9.24.3. Financial Overview
    • 9.24.4 Product Listing
    • 9.24.5. Entropy
  • 9.25 BONESUPPORT AB
    • 9.25.1. Company Overview
    • 9.25.2. Company Snapshot
    • 9.25.3. Financial Overview
    • 9.25.4 Product Listing
    • 9.25.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Orthobiologics Market
  • Table 3 Orthobiologics Market Analysis in Global (2018-2030)
  • Table 4 Orthobiologics Market Analysis in Global by Product Type (2018-2030)
  • Table 5 Orthobiologics Market Analysis in Global by Application (2018-2030)
  • Table 6 Orthobiologics Market Analysis in Global by End User (2018-2030)
  • Table 7 Orthobiologics Market Analysis in Global by Geography (2018-2030)
  • Table 8 Orthobiologics Market Analysis in North America (2018-2030)
  • Table 9 Orthobiologics Market Analysis in North America by Product Type (2018-2030)
  • Table 10 Orthobiologics Market Analysis in North America by Application (2018-2030)
  • Table 11 Orthobiologics Market Analysis in North America by End User (2018-2030)
  • Table 12 Orthobiologics Market Analysis in North America by Country (2018-2030)
  • Table 13 Orthobiologics Market Analysis in the US (2018-2030)
  • Table 14 Orthobiologics Market Analysis in Canada (2018-2030)
  • Table 15 Orthobiologics Market Analysis in Mexico (2018-2030)
  • Table 16 Orthobiologics Market Analysis in Europe (2018-2030)
  • Table 17 Orthobiologics Market Analysis in Europe by Product Type (2018-2030)
  • Table 18 Orthobiologics Market Analysis in Europe by Application (2018-2030)
  • Table 19 Orthobiologics Market Analysis in Europe by End User (2018-2030)
  • Table 20 Orthobiologics Market Analysis in Europe by Country (2018-2030)
  • Table 21 Orthobiologics Market Analysis in France (2018-2030)
  • Table 22 Orthobiologics Market Analysis in Germany (2018-2030)
  • Table 23 Orthobiologics Market Analysis in the UK (2018-2030)
  • Table 24 Orthobiologics Market Analysis in Italy (2018-2030)
  • Table 25 Orthobiologics Market Analysis in Spain (2018-2030)
  • Table 26 Orthobiologics Market Analysis in Russia (2018-2030)
  • Table 27 Orthobiologics Market Analysis in Rest of Europe (2018-2030)
  • Table 28 Orthobiologics Market Analysis in Asia-Pacific (2018-2030)
  • Table 29 Orthobiologics Market Analysis in Asia-Pacific by Product Type (2018-2030)
  • Table 30 Orthobiologics Market Analysis in Asia-Pacific by Application (2018-2030)
  • Table 31 Orthobiologics Market Analysis in Asia-Pacific by End User (2018-2030)
  • Table 32 Orthobiologics Market Analysis in Asia-Pacific by Country (2018-2030)
  • Table 33 Orthobiologics Market Analysis in China (2018-2030)
  • Table 34 Orthobiologics Market Analysis in Japan (2018-2030)
  • Table 35 Orthobiologics Market Analysis in India (2018-2030)
  • Table 36 Orthobiologics Market Analysis in Australia (2018-2030)
  • Table 37 Orthobiologics Market Analysis in South Korea (2018-2030)
  • Table 38 Orthobiologics Market Analysis in Rest of Asia-Pacific (2018-2030)
  • Table 39 Orthobiologics Market Analysis in Rest of World (2018-2030)
  • Table 40 Orthobiologics Market Analysis in Rest of World by Product Type (2018-2030)
  • Table 41 Orthobiologics Market Analysis in Rest of World by Application (2018-2030)
  • Table 42 Orthobiologics Market Analysis in Rest of World by End User (2018-2030)
  • Table 43 Orthobiologics Market Analysis in Rest of World by Country (2018-2030)
  • Table 44 Orthobiologics Market Analysis in the Middle East (2018-2030)
  • Table 45 Orthobiologics Market Analysis in Africa (2018-2030)
  • Table 46 Orthobiologics Market Analysis in South America (2018-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Orthobiologics Market
  • Figure 3 Orthobiologics Market Analysis in Global (2018-2030)
  • Figure 4 Orthobiologics Market Analysis in Global by Product Type (2018-2030)
  • Figure 5 Orthobiologics Market Analysis in Global by Application (2018-2030)
  • Figure 6 Orthobiologics Market Analysis in Global by End User (2018-2030)
  • Figure 7 Orthobiologics Market Analysis in Global by Geography (2018-2030)
  • Figure 8 Orthobiologics Market Analysis in North America (2018-2030)
  • Figure 9 Orthobiologics Market Analysis in North America by Product Type (2018-2030)
  • Figure 10 Orthobiologics Market Analysis in North America by Application (2018-2030)
  • Figure 11 Orthobiologics Market Analysis in North America by End User (2018-2030)
  • Figure 12 Orthobiologics Market Analysis in North America by Country (2018-2030)
  • Figure 13 Orthobiologics Market Analysis in the US (2018-2030)
  • Figure 14 Orthobiologics Market Analysis in Canada (2018-2030)
  • Figure 15 Orthobiologics Market Analysis in Mexico (2018-2030)
  • Figure 16 Orthobiologics Market Analysis in Europe (2018-2030)
  • Figure 17 Orthobiologics Market Analysis in Europe by Product Type (2018-2030)
  • Figure 18 Orthobiologics Market Analysis in Europe by Application (2018-2030)
  • Figure 19 Orthobiologics Market Analysis in Europe by End User (2018-2030)
  • Figure 20 Orthobiologics Market Analysis in Europe by Country (2018-2030)
  • Figure 21 Orthobiologics Market Analysis in France (2018-2030)
  • Figure 22 Orthobiologics Market Analysis in Germany (2018-2030)
  • Figure 23 Orthobiologics Market Analysis in the UK (2018-2030)
  • Figure 24 Orthobiologics Market Analysis in Italy (2018-2030)
  • Figure 25 Orthobiologics Market Analysis in Spain (2018-2030)
  • Figure 26 Orthobiologics Market Analysis in Russia (2018-2030)
  • Figure 27 Orthobiologics Market Analysis in Rest of Europe (2018-2030)
  • Figure 28 Orthobiologics Market Analysis in Asia-Pacific (2018-2030)
  • Figure 29 Orthobiologics Market Analysis in Asia-Pacific by Product Type (2018-2030)
  • Figure 30 Orthobiologics Market Analysis in Asia-Pacific by Application (2018-2030)
  • Figure 31 Orthobiologics Market Analysis in Asia-Pacific by End User (2018-2030)
  • Figure 32 Orthobiologics Market Analysis in Asia-Pacific by Country (2018-2030)
  • Figure 33 Orthobiologics Market Analysis in China (2018-2030)
  • Figure 34 Orthobiologics Market Analysis in Japan (2018-2030)
  • Figure 35 Orthobiologics Market Analysis in India (2018-2030)
  • Figure 36 Orthobiologics Market Analysis in Australia (2018-2030)
  • Figure 37 Orthobiologics Market Analysis in South Korea (2018-2030)
  • Figure 38 Orthobiologics Market Analysis in Rest of Asia-Pacific (2018-2030)
  • Figure 39 Orthobiologics Market Analysis in Rest of World (2018-2030)
  • Figure 40 Orthobiologics Market Analysis in Rest of World by Product Type (2018-2030)
  • Figure 41 Orthobiologics Market Analysis in Rest of World by Application (2018-2030)
  • Figure 42 Orthobiologics Market Analysis in Rest of World by End User (2018-2030)
  • Figure 43 Orthobiologics Market Analysis in Rest of World by Country (2018-2030)
  • Figure 44 Orthobiologics Market Analysis in the Middle East (2018-2030)
  • Figure 45 Orthobiologics Market Analysis in Africa (2018-2030)
  • Figure 46 Orthobiologics Market Analysis in South America (2018-2030)
  • Figure 47 Market Drivers
  • Figure 48 Market Barriers
  • Figure 49 Market Opportunities
  • Figure 50 PORTER's Five Force Analysis